EA202092962A1 - Производные пиразола в качестве ингибиторов malt1 - Google Patents

Производные пиразола в качестве ингибиторов malt1

Info

Publication number
EA202092962A1
EA202092962A1 EA202092962A EA202092962A EA202092962A1 EA 202092962 A1 EA202092962 A1 EA 202092962A1 EA 202092962 A EA202092962 A EA 202092962A EA 202092962 A EA202092962 A EA 202092962A EA 202092962 A1 EA202092962 A1 EA 202092962A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrazol derivatives
malt1 inhibitors
malt1
inhibitors
pyrazol
Prior art date
Application number
EA202092962A
Other languages
English (en)
Inventor
Тяньбао Лу
Питер Дж. Коннолли
Максвелл Дэвид Каммингс
Гастон Станислас Марселла Дилс
Ян Виллем Тюринг
Ульрике Филиппар
Джеймс Патрик Эдвардс
Дидье Жан-Клод Бертело
Тонгфей Ву
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA202092962A1 publication Critical patent/EA202092962A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Описаны соединения, составы и способы лечения заболеваний, синдромов, состояний и расстройств, которые зависят от модулирования MALT1. Такие соединения представлены формулой (I), где R1, R2, R3, R4, R5, R6, R7, G1 и G2 определены в настоящем документе.
EA202092962A 2018-06-18 2019-06-13 Производные пиразола в качестве ингибиторов malt1 EA202092962A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862686451P 2018-06-18 2018-06-18
PCT/IB2019/054965 WO2019243965A1 (en) 2018-06-18 2019-06-13 Pyrazole derivatives as malt1 inhibitors

Publications (1)

Publication Number Publication Date
EA202092962A1 true EA202092962A1 (ru) 2021-09-06

Family

ID=67688806

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092962A EA202092962A1 (ru) 2018-06-18 2019-06-13 Производные пиразола в качестве ингибиторов malt1

Country Status (13)

Country Link
US (1) US10888550B2 (ru)
EP (1) EP3810609A1 (ru)
JP (1) JP7296407B2 (ru)
KR (1) KR20210024002A (ru)
CN (1) CN112601747B (ru)
AU (1) AU2019289223B2 (ru)
BR (1) BR112020025814A2 (ru)
CA (1) CA3104055A1 (ru)
EA (1) EA202092962A1 (ru)
IL (1) IL279452B (ru)
MX (1) MX2020013699A (ru)
PH (1) PH12020552206A1 (ru)
WO (1) WO2019243965A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210024548A (ko) * 2018-06-18 2021-03-05 얀센 파마슈티카 엔.브이. Malt1 억제제로서의 피라졸 유도체
MX2021012417A (es) 2019-04-11 2021-11-12 Janssen Pharmaceutica Nv Anillos de piridina que contienen derivados como inhibidores de malt1.
CN117120427A (zh) * 2021-06-18 2023-11-24 上海拓界生物医药科技有限公司 一种malt1抑制剂及其制备方法和用途
WO2023125877A1 (zh) * 2021-12-30 2023-07-06 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339099B1 (en) 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
FR2795726A1 (fr) 1999-06-30 2001-01-05 Aventis Cropscience Sa Nouveaux pyrazoles fongicides
CA2465207C (en) 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides and -sulfonamides
EP1620108B1 (en) 2003-05-01 2012-06-06 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
JP2009542809A (ja) 2006-07-12 2009-12-03 メルク エンド カムパニー インコーポレーテッド グレリン受容体アンタゴニストとしての置換ピラゾール
CN102224149B (zh) 2008-09-24 2014-09-10 巴斯夫欧洲公司 防治无脊椎动物害虫的吡唑化合物
PT3149001T (pt) * 2014-05-28 2019-07-25 Novartis Ag Novos derivados de pirazolee pirimidina e seu uso como inibidores de malt1
WO2016062790A1 (en) * 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv New pyrazolopyrimidine derivatives as nik inhibitors
HUE046888T2 (hu) * 2014-10-30 2020-03-30 Janssen Pharmaceutica Nv Amid-szubsztituált tiazolok mint ROR-gamma-t modulátorok
WO2017040304A1 (en) * 2015-08-28 2017-03-09 Cornell University Malt1 inhibitors and uses thereof
WO2017057695A1 (ja) * 2015-09-30 2017-04-06 東レ株式会社 ジフェニルピラゾール誘導体及びその医薬用途
US20200289514A1 (en) * 2015-11-13 2020-09-17 Novartis Ag Novel Pyrazolo Pyrimidine Derivatives
CA3032334A1 (en) * 2016-07-29 2018-02-01 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物

Also Published As

Publication number Publication date
PH12020552206A1 (en) 2021-06-28
IL279452B (en) 2022-06-01
US20190381012A1 (en) 2019-12-19
CA3104055A1 (en) 2019-12-26
AU2019289223A1 (en) 2021-01-07
CN112601747A (zh) 2021-04-02
JP2021528401A (ja) 2021-10-21
WO2019243965A1 (en) 2019-12-26
MX2020013699A (es) 2021-05-12
IL279452A (en) 2021-01-31
BR112020025814A2 (pt) 2021-04-06
CN112601747B (zh) 2023-02-21
EP3810609A1 (en) 2021-04-28
JP7296407B2 (ja) 2023-06-22
AU2019289223B2 (en) 2023-09-21
KR20210024002A (ko) 2021-03-04
US10888550B2 (en) 2021-01-12

Similar Documents

Publication Publication Date Title
MX2022005827A (es) Derivados de pirazol como inhibidores de malt1.
EA202190055A1 (ru) Производные пиразола в качестве ингибиторов malt1
EA202092962A1 (ru) Производные пиразола в качестве ингибиторов malt1
PH12021551065A1 (en) Fused ring compounds
EA202091479A1 (ru) Арил- и гетероарилзамещенные индольные соединения
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA202091484A1 (ru) 4-азаиндольные соединения
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
EA202191519A1 (ru) Модуляторы trex1
EA202191104A1 (ru) Производные аминопиридина/пиразина в качестве ингибиторов ctps1
EA202092086A1 (ru) Ингибиторы аргиназы
EA201991700A1 (ru) Селективные ингибиторы jak1
EA201990400A1 (ru) Соединения и композиции и их применение
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
EA201790800A1 (ru) Замещенные производные бензотиофенила в качестве агонистов gpr40 для лечения диабета ii типа
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
EA202090414A1 (ru) Соединения и их применение
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
EA202190271A1 (ru) Замещенные триазолохиноксалиновые производные
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
EA202190298A1 (ru) Циклические динуклеотиды в качестве агонистов sting
EA202092446A1 (ru) ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34
MX2021012417A (es) Anillos de piridina que contienen derivados como inhibidores de malt1.
EA202090438A1 (ru) Производные глицерретиновой кислоты для лечения гиперкалиемии